274 related articles for article (PubMed ID: 31498947)
21. The effects of sample handling and N-phenylmaleimide on concentration of adrenocorticotrophic hormone in equine plasma.
Rendle DI; Litchfield E; Gough S; Cowling A; Hughes KJ
Equine Vet J; 2015 Sep; 47(5):587-91. PubMed ID: 24980684
[TBL] [Abstract][Full Text] [Related]
22. Effect of delayed plasma centrifugation on equine adrenocorticotropic hormone concentration.
Shepard KN; Haffner JC; Neal DL; Grubbs ST; Pearce GL
J Vet Diagn Invest; 2019 Jul; 31(4):585-587. PubMed ID: 31246158
[TBL] [Abstract][Full Text] [Related]
23. Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses.
Miller AB; Loynachan AT; Bush HM; Hart KA; Barker VD; Campana-Emard AG; Grubbs ST; Adams AA
Domest Anim Endocrinol; 2021 Jan; 74():106531. PubMed ID: 32942194
[TBL] [Abstract][Full Text] [Related]
24. Circannual variation in plasma adrenocorticotropic hormone concentrations in the UK in normal horses and ponies, and those with pituitary pars intermedia dysfunction.
Copas VE; Durham AE
Equine Vet J; 2012 Jul; 44(4):440-3. PubMed ID: 21848531
[TBL] [Abstract][Full Text] [Related]
25. The use of adrenocorticotrophic hormone as a potential biomarker of pituitary pars intermedia dysfunction in horses.
Lee ZY; Zylstra R; Haritou SJ
Vet J; 2010 Jul; 185(1):58-61. PubMed ID: 20537574
[TBL] [Abstract][Full Text] [Related]
26. Pituitary pars intermedia dysfunction does not necessarily impair insulin sensitivity in old horses.
Mastro LM; Adams AA; Urschel KL
Domest Anim Endocrinol; 2015 Jan; 50():14-25. PubMed ID: 25240230
[TBL] [Abstract][Full Text] [Related]
27. Basal glucose metabolism and peripheral insulin sensitivity in equine pituitary pars intermedia dysfunction.
Klinkhamer K; Menheere PP; van der Kolk JH
Vet Q; 2011 Mar; 31(1):19-28. PubMed ID: 22029818
[TBL] [Abstract][Full Text] [Related]
28. The effect of pergolide mesylate on adrenocorticotrophic hormone responses to exogenous thyrotropin releasing hormone in horses.
Durham AE
Vet J; 2022 Jul; 285():105831. PubMed ID: 35477010
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of plasma ACTH, alpha-melanocyte-stimulating hormone, and insulin concentrations during various photoperiods in clinically normal horses and ponies and those with pituitary pars intermedia dysfunction.
Beech J; Boston RC; McFarlane D; Lindborg S
J Am Vet Med Assoc; 2009 Sep; 235(6):715-22. PubMed ID: 19751169
[TBL] [Abstract][Full Text] [Related]
30. Impact of blue light therapy on plasma adrenocorticotropic hormone (ACTH) and hypertrichosis in horses with pituitary pars intermedia dysfunction.
Miller AB; Murphy BA; Adams AA
Domest Anim Endocrinol; 2022 Jan; 78():106651. PubMed ID: 34656964
[TBL] [Abstract][Full Text] [Related]
31. Effect of Age, Season, Body Condition, and Endocrine Status on Serum Free Cortisol Fraction and Insulin Concentration in Horses.
Hart KA; Wochele DM; Norton NA; McFarlane D; Wooldridge AA; Frank N
J Vet Intern Med; 2016; 30(2):653-63. PubMed ID: 26860336
[TBL] [Abstract][Full Text] [Related]
32. Relationships of inflamm-aging with circulating nutrient levels, body composition, age, and pituitary pars intermedia dysfunction in a senior horse population.
Siard-Altman MH; Harris PA; Moffett-Krotky AD; Ireland JL; Betancourt A; Barker VD; McMurry KE; Reedy SE; Adams AA
Vet Immunol Immunopathol; 2020 Mar; 221():110013. PubMed ID: 32058159
[TBL] [Abstract][Full Text] [Related]
33. Comparison of two methods for measurement of equine adrenocorticotropin.
Banse HE; Schultz N; McCue M; Geor R; McFarlane D
J Vet Diagn Invest; 2018 Mar; 30(2):233-237. PubMed ID: 29284383
[TBL] [Abstract][Full Text] [Related]
34. Association of season and pasture grazing with blood hormone and metabolite concentrations in horses with presumed pituitary pars intermedia dysfunction.
Frank N; Elliott SB; Chameroy KA; Tóth F; Chumbler NS; McClamroch R
J Vet Intern Med; 2010; 24(5):1167-75. PubMed ID: 20666984
[TBL] [Abstract][Full Text] [Related]
35. Effects of withholding feed on thyrotropin-releasing hormone stimulation test results and effects of combined testing on oral sugar test and thyrotropin-releasing hormone stimulation test results in horses.
Restifo MM; Frank N; Hermida P; Sanchez-Londoño A
Am J Vet Res; 2016 Jul; 77(7):738-48. PubMed ID: 27347827
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction.
Rendle DI; Doran G; Ireland J; Edwards S
Domest Anim Endocrinol; 2019 Jul; 68():135-141. PubMed ID: 31082785
[TBL] [Abstract][Full Text] [Related]
37. Influence of feeding and other factors on adrenocorticotropin concentration and thyrotropin-releasing hormone stimulation test in horses and ponies.
Drozdzewska K; Winter J; Barton AK; Merle R; Gehlen H
Equine Vet J; 2024 Mar; 56(2):342-351. PubMed ID: 38010866
[TBL] [Abstract][Full Text] [Related]
38. Correlation of pituitary histomorphometry with adrenocorticotrophic hormone response to domperidone administration in the diagnosis of equine pituitary pars intermedia dysfunction.
Miller MA; Pardo ID; Jackson LP; Moore GE; Sojka JE
Vet Pathol; 2008 Jan; 45(1):26-38. PubMed ID: 18192571
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the sensitivity and specificity of basal plasma adrenocorticotrophic hormone concentration for diagnosing pituitary pars intermedia dysfunction in horses: A systematic review.
Tatum RC; McGowan CM; Ireland JL
Vet J; 2021 Sep; 275():105695. PubMed ID: 34099343
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of basal plasma α-melanocyte-stimulating hormone and adrenocorticotrophic hormone concentrations for the diagnosis of pituitary pars intermedia dysfunction from a population of aged horses.
Mc Gowan TW; Pinchbeck GP; Mc Gowan CM
Equine Vet J; 2013 Jan; 45(1):66-73. PubMed ID: 22563728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
